Edwards Lifesciences Corp (EW)

Intuitive Surgical (ISRG) is prioritizing aggressive investment in research and development (R&D) to ensure long-term growth, despite current macroeconomic challenges and competitive pressures. This strategy focuses on innovation, including AI/ML and robotics, to expand into new disease areas like GI, cardiac, and lung interventions, rather than short-term cost-cutting. The company believes this will broaden its addressable market and strengthen its competitive moat, similar to peers like Edwards Lifesciences and Glaukos who also maintain substantial R&D spending.

Van ECK Associates Corp reduced its stake in Edwards Lifesciences Corporation by 9.8% in Q2 2026, selling 13,722 shares but still retaining over $11.4 million worth of stock. Despite this, institutional investors hold a significant 79.46% of the company's shares. Edwards Lifesciences reported strong Q2 earnings, beating estimates with $0.78 EPS and a 13.6% revenue increase to $1.74 billion, leading analysts to maintain a "Moderate Buy" rating with an average price target of $100.27.

NS Partners Ltd significantly reduced its stake in Edwards Lifesciences Corporation by 32.3% in the second quarter, selling over 62,000 shares. Despite this, the company reported strong quarterly earnings, exceeding analyst expectations with $0.78 EPS and a 13.6% revenue increase year-over-year. Analyst sentiment for Edwards Lifesciences remains positive, with a consensus "Moderate Buy" rating and an average price target of $100.27, although company insiders have recently sold shares.

Andrew M. Dahl, SVP, Corporate Controller at Edwards Lifesciences Corp (NASDAQ:EW), sold 544 shares of company stock for a total of $49,533 on August 31, 2026, at a price of $91.055 per share. This transaction leaves Mr. Dahl with 14,868.41 shares. The sale occurred while the stock was near its 52-week high, and InvestingPro data suggests the shares are slightly overvalued.

Andrew M. Dahl, Senior Vice President and Corporate Controller at Edwards Lifesciences Corp, sold 544 shares of common stock at $91.055 per share on August 31, 2026, under the company's Employee Stock Purchase Plan. Following this transaction, Dahl directly owns 14,868.41 shares of Edwards Lifesciences. This transaction was disclosed via an SEC Form 4 and reflects routine quarterly share acquisitions.